

Shereen Ezzat

List of Publications by Citations

Source: <https://exaly.com/author-pdf/10615152/shereen-ezzat-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

283
papers

11,638
citations

57
h-index

99
g-index

300
ext. papers

12,906
ext. citations

6
avg, IF

6.3
L-index

#	Paper	IF	Citations
283	The prevalence of pituitary adenomas: a systematic review. <i>Cancer</i> , 2004 , 101, 613-9	6.4	885
282	Pathogenetic mechanisms in thyroid follicular-cell neoplasia. <i>Nature Reviews Cancer</i> , 2006 , 6, 292-306	31.3	674
281	Thyroid Incidentalomas. <i>Archives of Internal Medicine</i> , 1994 , 154, 1838		384
280	The pathogenesis of pituitary tumours. <i>Nature Reviews Cancer</i> , 2002 , 2, 836-49	31.3	276
279	Immunohistochemical diagnosis of papillary thyroid carcinoma. <i>Modern Pathology</i> , 2001 , 14, 338-42	9.8	265
278	The cytogenesis and pathogenesis of pituitary adenomas. <i>Endocrine Reviews</i> , 1998 , 19, 798-827	27.2	251
277	Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. <i>Thyroid</i> , 2009 , 19, 451-7	6.2	244
276	Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 4116-22	5.6	215
275	Cystic lesions of the pituitary: clinicopathological features distinguishing craniopharyngioma, Rathke's cleft cyst, and arachnoid cyst. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 3972-82	5.6	190
274	The pathogenesis of pituitary tumors. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2009 , 4, 97-126	34	185
273	Octreotide treatment of acromegaly. A randomized, multicenter study. <i>Annals of Internal Medicine</i> , 1992 , 117, 711-8	8	184
272	The spectrum and significance of primary hypophysitis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 1048-53	5.6	155
271	Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 2187-90	5.6	150
270	The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. <i>Endocrine Reviews</i> , 2006 , 27, 287-317	27.2	140
269	The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 6290-5	5.6	139
268	A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. <i>Clinical Endocrinology</i> , 2008 , 69, 479-90	3.4	129
267	Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 5-9	5.6	128

266	Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2002 , 109, 69-78	15.9	124
265	Clinical review 18: Are patients with acromegaly at increased risk for neoplasia?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 72, 245-9	5.6	118
264	Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1814-8	5.6	113
263	The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. <i>Cancer Research</i> , 2008 , 68, 8104-12	10.1	108
262	Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. <i>Thyroid</i> , 2007 , 17, 1277-88	6.2	106
261	Biomarkers of aggressive pituitary adenomas. <i>Journal of Molecular Endocrinology</i> , 2012 , 49, R69-78	4.5	105
260	Altered expression of fibroblast growth factor receptors in human pituitary adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 1160-6	5.6	104
259	Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. <i>Endocrinology</i> , 2005 , 146, 1145-53	4.8	104
258	Myostatin is a skeletal muscle target of growth hormone anabolic action. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5490-6	5.6	102
257	Clonality of thyroid nodules in sporadic goiter. <i>Diagnostic Molecular Pathology</i> , 1995 , 4, 113-21		101
256	Molecular basis off hurthle cell papillary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 878-82	5.6	99
255	A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. <i>Clinical Endocrinology</i> , 2009 , 71, 549-57	3.4	96
254	Acromegaly: re-thinking the cancer risk. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2008 , 9, 41-58	10.5	93
253	Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1745-51	5.6	92
252	In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. <i>European Journal of Endocrinology</i> , 1995 , 133, 686-90	6.5	92
251	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. <i>Nature Genetics</i> , 2018 , 50, 979-989	36.3	90
250	Prevalence of activating ras mutations in morphologically characterized thyroid nodules. <i>Thyroid</i> , 1996 , 6, 409-16	6.2	90
249	Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. <i>Modern Pathology</i> , 2016 , 29, 131-42	9.8	86

248	Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 4570-7	5.6	85
247	Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. <i>Cancer Research</i> , 2009 , 69, 2739-47	10.1	81
246	Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1810-3	5.6	78
245	Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. <i>American Journal of Pathology</i> , 2002 , 160, 511-9	5.8	74
244	Oncogene profile of papillary thyroid carcinoma. <i>Surgery</i> , 1999 , 125, 46-52	3.6	73
243	Mechanisms of disease: The pathogenesis of pituitary tumors. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006 , 2, 220-30		72
242	AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. <i>Endocrine Practice</i> , 2004 , 10, 213-25	3.2	72
241	Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. <i>Molecular Endocrinology</i> , 2004 , 18, 2543-52		71
240	The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	71
239	Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter. <i>American Journal of Pathology</i> , 2003 , 163, 1177-84 ⁵⁸		69
238	Controversies in papillary microcarcinoma of the thyroid. <i>Endocrine Pathology</i> , 2003 , 14, 183-91	4.2	67
237	Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 340-352	4	64
236	A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. <i>Clinical Endocrinology</i> , 2008 , 68, 610-7	3.4	63
235	Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. <i>Clinical Cancer Research</i> , 2008 , 14, 1984-96	12.9	62
234	Colon polyps in acromegaly. <i>Annals of Internal Medicine</i> , 1991 , 114, 754-5	8	62
233	A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. <i>Cancer Research</i> , 2007 , 67, 7505-11	10.1	61
232	Improved diagnostic accuracy of inferior petrosal sinus sampling over imaging for localizing pituitary pathology in patients with Cushing's disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2291-5	5.6	61
231	Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. <i>Cancer Research</i> , 2007 , 67, 5461-70	10.1	60

230	Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. <i>American Journal of Pathology</i> , 2007 , 170, 1618-28	5.8	60
229	A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. <i>Clinical Cancer Research</i> , 2011 , 17, 2385-94	12.9	58
228	Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. <i>Cancer Treatment Reviews</i> , 2016 , 47, 32-45	14.4	57
227	Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. <i>Thyroid</i> , 2010 , 20, 1129-38	6.2	56
226	The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. <i>PLoS Genetics</i> , 2011 , 7, e1002400	6	56
225	Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1904-11	5.6	56
224	Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. <i>Clinical Cancer Research</i> , 2005 , 11, 1336-41	12.9	56
223	Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice. <i>American Journal of Pathology</i> , 2000 , 156, 1009-15	5.8	55
222	Effect of octreotide on glucose tolerance in acromegaly. <i>European Journal of Endocrinology</i> , 1994 , 130, 581-6	6.5	55
221	Cancer-related worry in Canadian thyroid cancer survivors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 977-85	5.6	54
220	The MEN-1 gene is rarely down-regulated in pituitary adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 3210-2	5.6	53
219	Basic Fibroblast Growth Factor Expression by Two Prolactin and Thyrotropin-Producing Pituitary Adenomas. <i>Endocrine Pathology</i> , 1995 , 6, 125-134	4.2	53
218	Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. <i>Endocrinology</i> , 2004 , 145, 5840-6 ^{4.8}	4.8	52
217	Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. <i>Clinical Endocrinology</i> , 2012 , 76, 264-71	3.4	51
216	The endogenous fibroblast growth factor-2 antisense gene product regulates pituitary cell growth and hormone production. <i>Molecular Endocrinology</i> , 2001 , 15, 589-99		50
215	A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. <i>Blood</i> , 2007 , 110, 4047-54	2.2	48
214	The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study. <i>PLoS ONE</i> , 2009 , 4, e4191	3.7	47
213	Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. <i>Cancer Research</i> , 2008 , 68, 6688-97	10.1	46

212	The role of hormones, growth factors and their receptors in pituitary tumorigenesis. <i>Brain Pathology</i> , 2001 , 11, 356-70	6	46
211	Diagnosis and management of hyperprolactinemia. <i>Cmaj</i> , 2003 , 169, 575-81	3.5	46
210	The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. <i>Endocrine-Related Cancer</i> , 2014 , 21, R331-44	5.7	44
209	Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2014 , 138, 182-8	5	44
208	Cushing's Syndrome from an Ectopic Pituitary Adenoma with Peliosis: A Histological, Immunohistochemical, and Ultrastructural Study and Review of the Literature. <i>Endocrine Pathology</i> , 1997 , 8, 65-74	4.2	44
207	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. <i>British Journal of Cancer</i> , 2019 , 120, 1113-1119	8.7	42
206	1 α ,25-Dihydroxyvitamin D ₃ targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. <i>Molecular Endocrinology</i> , 2005 , 19, 2349-57		42
205	Molecular determinants of pituitary cytodifferentiation. <i>Pituitary</i> , 1999 , 1, 159-68	4.3	42
204	The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. <i>Cancer Research</i> , 2012 , 72, 5683-91	10.1	41
203	The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 4713-20	12.9	41
202	An essential role for the hematopoietic transcription factor Ikaros in hypothalamic-pituitary-mediated somatic growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 2214-9	11.5	39
201	Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. <i>Molecular Endocrinology</i> , 2006 , 20, 2965-75		39
200	Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 73, 441-3	5.6	39
199	The c-erbB-2/neu proto-oncogene in human pituitary tumours. <i>Clinical Endocrinology</i> , 1997 , 46, 599-606	3.4	38
198	Pancreatic endocrine pathology in von Hippel-Lindau disease: an expanding spectrum of lesions. <i>Endocrine Pathology</i> , 2004 , 15, 141-8	4.2	38
197	Pituitary tumor AP-2 α recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4. <i>Journal of Biological Chemistry</i> , 2003 , 278, 19597-602	5.4	37
196	Distinct clonal composition of primary and metastatic adrenocorticotrophic hormone-producing pituitary carcinoma. <i>Clinical Endocrinology</i> , 2001 , 55, 549-56	3.4	37
195	Ikaros integrates endocrine and immune system development. <i>Journal of Clinical Investigation</i> , 2005 , 115, 1021-1029	15.9	37

194	Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3610-7	5.6	36
193	Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. <i>Human Pathology</i> , 2007 , 38, 1810-8	3.7	36
192	Molecular basis of pituitary development and cytogenesis. <i>Frontiers of Hormone Research</i> , 2004 , 32, 1-19	3.5	36
191	The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility. <i>Molecular Endocrinology</i> , 2005 , 19, 1004-11		36
190	Psychological features of acromegaly. <i>Psychotherapy and Psychosomatics</i> , 1998 , 67, 147-53	9.4	35
189	Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells. <i>Molecular Endocrinology</i> , 2006 , 20, 2976-86		35
188	Fibroblast growth factor receptor 4 is a target for the zinc-finger transcription factor Ikaros in the pituitary. <i>Molecular Endocrinology</i> , 2002 , 16, 1069-78		35
187	Treatment Options for Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2019 , 11,	6.6	33
186	Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. <i>Expert Review of Endocrinology and Metabolism</i> , 2016 , 11, 149-162	4.1	33
185	A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2001 , 287, 60-5	3.4	33
184	A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. <i>Thyroid</i> , 2018 , 28, 1662-1673	6.2	33
183	Autoimmune hypophysitis. <i>Trends in Endocrinology and Metabolism</i> , 1997 , 8, 74-80	8.8	32
182	Growth patterns of pituitary adenomas and histopathological correlates. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 1330-8	5.6	31
181	Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015 , 466, 727-32	5.1	30
180	An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. <i>Endocrine Pathology</i> , 2019 , 30, 118-127	4.2	28
179	The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas. <i>Endocrine Pathology</i> , 2013 , 24, 191-8	4.2	28
178	Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells. <i>Brain Pathology</i> , 2002 , 12, 412-9	6	28
177	Genetics and proteomics of pituitary tumors. <i>Endocrine</i> , 2005 , 28, 43-7		28

176	Protocol for the examination of specimens from patients with primary pituitary tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2011 , 135, 640-6	5	28
175	Pituitary acromegaly: not one disease. <i>Endocrine-Related Cancer</i> , 2017 , 24, C1-C4	5.7	27
174	Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor. <i>Cancer</i> , 1993 , 71, 66-70	6.4	27
173	Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior. <i>Cancer Medicine</i> , 2013 , 2, 701-11	4.8	25
172	Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. <i>Molecular Endocrinology</i> , 2009 , 23, 1397-405		25
171	Epigenetic control in pituitary tumors. <i>Endocrine Journal</i> , 2008 , 55, 951-7	2.9	25
170	AIP Mutations are not identified in patients with sporadic pituitary adenomas. <i>Endocrine Pathology</i> , 2007 , 18, 76-8	4.2	25
169	Emerging trends in the diagnosis and treatment of acromegaly in Canada. <i>Clinical Endocrinology</i> , 2013 , 79, 79-85	3.4	24
168	Epigenetic dysregulation in thyroid neoplasia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008 , 37, 389-400, ix	5.5	24
167	Exercise training benefits growth hormone (GH)-deficient adults in the absence or presence of GH treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5734-8	5.6	24
166	Pituitary Adenomas Presenting as Sinonasal or Nasopharyngeal Masses: A Case Series Illustrating Potential Diagnostic Pitfalls. <i>American Journal of Surgical Pathology</i> , 2017 , 41, 525-534	6.7	23
165	Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippel-Lindau disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013 , 463, 593-7	5.1	23
164	FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. <i>Cancer Research</i> , 2012 , 72, 2017-27	10.1	23
163	Ikaros modulates cholesterol uptake: a link between tumor suppression and differentiation. <i>Cancer Research</i> , 2008 , 68, 3715-23	10.1	23
162	Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas		23
161	Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. <i>PLoS ONE</i> , 2013 , 8, e61538	3.7	23
160	The Clinicopathological Spectrum of Acromegaly. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	23
159	Hypothalamic Vasopressin-Producing Tumors: Often Inappropriate Diuresis But Occasionally Cushing Disease. <i>American Journal of Surgical Pathology</i> , 2019 , 43, 251-260	6.7	22

158	A Prospective Mixed-Methods Study of Decision-Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer. <i>Thyroid</i> , 2020 , 30, 999-1007	6.2	22
157	The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes. <i>Cell Metabolism</i> , 2013 , 17, 929-940	24.6	22
156	PREDICTIVE MARKERS FOR POSTSURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE. <i>Endocrine Practice</i> , 2019 , 25, 379-393	3.2	21
155	CtBP1 interacts with Ikaros and modulates pituitary tumor cell survival and response to hypoxia. <i>Molecular Endocrinology</i> , 2012 , 26, 447-57		21
154	Acromegaly. <i>Endocrinology and Metabolism Clinics of North America</i> , 1997 , 26, 703-23	5.5	21
153	Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess. <i>Clinical Endocrinology</i> , 2002 , 56, 351-8	3.4	21
152	The epigenetic landscape of differentiated thyroid cancer. <i>Molecular and Cellular Endocrinology</i> , 2018 , 469, 3-10	4.4	20
151	Persistent posttreatment fatigue in thyroid cancer survivors: a scoping review. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014 , 43, 475-94	5.5	19
150	The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF- κ B signaling. <i>Molecular and Cellular Biology</i> , 2012 , 32, 4662-73	4.8	19
149	Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005 , 289, E494-503	6	19
148	Growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) isoform expression in ectopic acromegaly. <i>Clinical Endocrinology</i> , 2001 , 55, 135-40	3.4	19
147	Longitudinal assessment of economic burden and clinical outcomes in acromegaly. <i>Endocrine Practice</i> , 2001 , 7, 170-80	3.2	19
146	A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology. <i>Endocrine Pathology</i> , 2019 , 30, 201-218	4.2	18
145	Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. <i>Clinical Endocrinology</i> , 1998 , 49, 629-37	3.4	18
144	A prospective multicenter octreotide dose response study in the treatment of acromegaly. <i>Journal of Endocrinological Investigation</i> , 1995 , 18, 364-9	5.2	18
143	Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.. <i>Endocrine Pathology</i> , 2022 , 33, 115-154	4.2	18
142	The emerging role of the Ikaros stem cell factor in the neuroendocrine system. <i>Journal of Molecular Endocrinology</i> , 2008 , 41, 45-51	4.5	17
141	Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey. <i>Endocrine Practice</i> , 2008 , 14, 175-84	3.2	17

140	Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications. <i>Molecular and Cellular Endocrinology</i> , 2018 , 469, 70-76	4.4	16
139	FGFR4 polymorphic variants modulate phenotypic features of Cushing disease. <i>Molecular Endocrinology</i> , 2014 , 28, 525-33		16
138	The role of diabetes in acromegaly associated neoplasia. <i>PLoS ONE</i> , 2015 , 10, e0127276	3.7	16
137	Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer. <i>Endocrine-Related Cancer</i> , 2009 , 16, 455-66	5.7	16
136	Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage. <i>Clinical Cancer Research</i> , 2004 , 10, 6750-8	12.9	16
135	A Systematic Review and Meta-Analysis of Patient Preferences for Combination Thyroid Hormone Treatment for Hypothyroidism. <i>Frontiers in Endocrinology</i> , 2019 , 10, 477	5.7	15
134	Functional cardiac paraganglioma associated with a rare SDHC mutation. <i>Endocrine Pathology</i> , 2014 , 25, 315-20	4.2	15
133	Chromatin remodeling and histone modifications in pituitary tumors. <i>Molecular and Cellular Endocrinology</i> , 2010 , 326, 66-70	4.4	15
132	Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. <i>American Journal of Pathology</i> , 2010 , 176, 2333-43	5.8	15
131	The cost of medical care for the acromegalic patient. <i>Neuroendocrinology</i> , 2006 , 83, 139-44	5.6	15
130	Ikaros integrates endocrine and immune system development. <i>Journal of Clinical Investigation</i> , 2005 , 115, 1021-9	15.9	15
129	Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. <i>Endocrine Pathology</i> , 2018 , 29, 332-338	4.2	15
128	Ikaros is regulated through multiple histone modifications and deoxyribonucleic acid methylation in the pituitary. <i>Molecular Endocrinology</i> , 2007 , 21, 1205-15		14
127	Circulating and synovial levels of IGF-I, cytokines, physical function and anthropometry differ in women awaiting total knee arthroplasty when compared to men. <i>Journal of Orthopaedic Research</i> , 2005 , 23, 397-405	3.8	14
126	Medical management of pituitary adenomas: structural and ultrastructural changes. <i>Pituitary</i> , 2002 , 5, 133-9	4.3	14
125	Living with Acromegaly. <i>Endocrinology and Metabolism Clinics of North America</i> , 1992 , 21, 753-760	5.5	14
124	Management of Lesions of the Pituitary Stalk and Hypothalamus 2003 , 13, 38-51		13
123	FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. <i>Oncotarget</i> , 2017 , 8, 3481-3494	3.3	13

122	The Clinicopathological Spectrum of Parathyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2019 , 10, 731	5.7	12
121	Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative action. <i>Laboratory Investigation</i> , 2011 , 91, 147-56	5.9	12
120	Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer--a randomized controlled trial. <i>Trials</i> , 2010 , 11, 81	2.8	12
119	Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States. <i>Thyroid</i> , 2007 , 17, 1235-42	6.2	12
118	Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5124-31	5.6	12
117	Distinct transcriptional control and action of fibroblast growth factor receptor 4 in differentiating skeletal muscle cells. <i>Laboratory Investigation</i> , 2004 , 84, 1571-80	5.9	12
116	Management of Small Bowel Neuroendocrine Tumors. <i>Cancers</i> , 2019 , 11,	6.6	11
115	Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow-up from a decision-aid randomized trial. <i>Cancer</i> , 2015 , 121, 3717-26	6.4	11
114	Unmet Information Needs of Low-Risk Thyroid Cancer Survivors. <i>Thyroid</i> , 2016 , 26, 474-5	6.2	11
113	Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. <i>Modern Pathology</i> , 2014 , 27, 1050-62	9.8	11
112	Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician. <i>Turk Patoloji Dergisi</i> , 2015 , 31 Suppl 1, 4-17	0.6	11
111	Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: a case report and literature review. <i>Endocrine Practice</i> , 2014 , 20, e145-50	3.2	11
110	Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. <i>Journal of Pathology</i> , 2009 , 218, 232-40	9.4	11
109	Mice lacking the transcription factor Ikaros display behavioral alterations of an anti-depressive phenotype. <i>Experimental Neurology</i> , 2008 , 211, 107-14	5.7	11
108	Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells. <i>Leukemia Research</i> , 2008 , 32, 1480-2	2.7	11
107	Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary		11
106	High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor. <i>Oncotarget</i> , 2016 , 7, 19948-59	3.3	11
105	Intrathyroidal Parathyroid Carcinoma: An Atypical Thyroid Lesion. <i>Frontiers in Endocrinology</i> , 2018 , 9, 641	5.7	11

104	Complex endocrinopathies in MEN-1: diagnostic dilemmas in endocrine oncology. <i>Endocrine Pathology</i> , 2007 , 18, 37-41	4.2	10
103	Continuous versus intermittent subcutaneous infusion of octreotide in the treatment of acromegaly. <i>Journal of Clinical Pharmacology</i> , 1995 , 35, 59-71	2.9	10
102	Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease. <i>Annals of Surgical Oncology</i> , 2019 , 26, 2533-2539	3.1	9
101	A systematic review of randomized controlled trials for management of persistent post-treatment fatigue in thyroid cancer survivors. <i>Thyroid</i> , 2015 , 25, 198-210	6.2	9
100	Genomic approaches to problems in pituitary neoplasia. <i>Endocrine Pathology</i> , 2014 , 25, 209-13	4.2	9
99	Dopaminergic resistant prolactinomas in the peripubertal population. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2006 , 19, 951-3	1.6	9
98	Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002 , 283, E490-5	6	9
97	Endocrine applications of the somatostatin analogue octreotide (Sandostatin). <i>Metabolism: Clinical and Experimental</i> , 1992 , 41, 34-8	12.7	9
96	Male occult triple-negative breast cancer with dermatomyositis: a case report and review of the literature. <i>OncoTargets and Therapy</i> , 2017 , 10, 5459-5462	4.4	8
95	Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly. <i>PLoS ONE</i> , 2013 , 8, e73543	3.7	8
94	Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer. <i>American Journal of Pathology</i> , 2010 , 177, 2860-9	5.8	8
93	Controversies in papillary microcarcinoma of the thyroid 2003 , 14, 183		8
92	A detailed spatial analysis on contrasting cancer incidence patterns in thyroid and lung cancer in Toronto women. <i>BMC Public Health</i> , 2016 , 16, 950	4.1	8
91	Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft. <i>Endocrine Pathology</i> , 2016 , 27, 97-103	4.2	8
90	Canadian consensus guidelines for the diagnosis and management of acromegaly. <i>Clinical and Investigative Medicine</i> , 2006 , 29, 29-39	0.9	8
89	Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis. <i>Journal of Cancer Survivorship</i> , 2019 , 13, 231-243	5.1	7
88	Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients. <i>Clinical Genetics</i> , 2019 , 96, 461-467	4	7
87	AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease. <i>Endocrine Practice</i> , 2014 , 20, 608-16	3.2	7

86	The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation. <i>Thyroid</i> , 2013 , 23, 246-7	6.2	7
85	Comparison of body composition assessment methods in patients with human immunodeficiency virus-associated wasting receiving growth hormone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2952-9	5.6	7
84	Microadenomatosis of the pancreas in von Hippel-Lindau disease. <i>American Journal of Surgical Pathology</i> , 2006 , 30, 1630; author reply 1630-1	6.7	7
83	Pituitary tumor pathogenesis--the hunt for novel candidate genes continues. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5116-8	5.6	7
82	Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. <i>Modern Pathology</i> , 2021 , 34, 1634-1650	9.8	7
81	Concerns of low-risk thyroid cancer survivors. <i>Acta Oncologica</i> , 2016 , 55, 1252-1253	3.2	7
80	NG2 targets tumorigenic Rb inactivation in Pit1-lineage pituitary cells. <i>Endocrine-Related Cancer</i> , 2016 , 23, 445-56	5.7	6
79	A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly. <i>Clinical and Investigative Medicine</i> , 2009 , 32, E265	0.9	6
78	Autoimmune Hypophysitis 1999 , 337-348		6
77	Exploring the relationship between patients' information preference style and knowledge acquisition process in a computerized patient decision aid randomized controlled trial. <i>BMC Medical Informatics and Decision Making</i> , 2015 , 15, 48	3.6	5
76	Endoscopic Endonasal Pituitary Surgery For Nonfunctioning Pituitary Adenomas: Long-Term Outcomes and Management of Recurrent Tumors. <i>World Neurosurgery</i> , 2021 , 146, e341-e350	2.1	5
75	Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?. <i>Endocrine Pathology</i> , 2021 , 32, 3-16	4.2	5
74	Pancreatic Neuroendocrine Tumor Producing Insulin and Vasopressin. <i>Endocrine Pathology</i> , 2018 , 29, 15-20	4.2	4
73	Primary mediastinal paraganglioma associated with a familial variant in the succinate dehydrogenase B subunit gene. <i>Journal of Surgical Oncology</i> , 2018 , 117, 160-162	2.8	4
72	A large and aggressive fibromatosis in the axilla: a rare case report and review of the literature. <i>OncoTargets and Therapy</i> , 2018 , 11, 3179-3184	4.4	4
71	Ikaros and its interacting partner CtBP target the metalloprotease ADAMTS10 to modulate pituitary cell function. <i>Molecular and Cellular Endocrinology</i> , 2017 , 439, 126-132	4.4	4
70	Managing newly diagnosed thyroid cancer. <i>Cmaj</i> , 2014 , 186, 269-75	3.5	4
69	[13C]NMR studies of the effect of the somatostatin analogue octreotide on hepatic glycogenesis and glycogenolysis. <i>Peptides</i> , 1994 , 15, 1223-7	3.8	4

68	Exploring the Life Impact of Treated Low-Risk Thyroid Cancer. <i>Endocrine Practice</i> , 2016 , 22, 513-4	3.2	4
67	The retrotransposon gag domain containing protein Rgag4 is an Ikaros target in the pituitary. <i>Molecular and Cellular Endocrinology</i> , 2018 , 461, 188-193	4.4	3
66	Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-up extension. <i>Trials</i> , 2015 , 16, 302	2.8	3
65	An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
64	Temporal trends in thyroid cancer incidence in California-letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2609	4	2
63	Clinical predictors of advanced sellar masses. <i>Endocrine Practice</i> , 2007 , 13, 609-14	3.2	2
62	Clinicopathological variations in cushing's syndrome. <i>Endocrine Pathology</i> , 1999 , 10, 165-71	4.2	2
61	The Management of Neuro-Endocrine Neoplasms 2021 , 461-469		2
60	Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease. <i>Frontiers in Endocrinology</i> , 2021 , 12, 620005	5.7	2
59	The Pangenomic Classification of Pituitary Neuroendocrine Tumors: Quality Histopathology is Required for Accurate Translational Research. <i>Endocrine Pathology</i> , 2021 , 32, 415-417	4.2	2
58	Hypothalamic hormone-producing tumors. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2021 , 181, 67-74	3	2
57	Symptom burden in adults with thyroid cancer. <i>Psycho-Oncology</i> , 2018 , 27, 2517-2519	3.9	1
56	Pancreatic Neuroendocrine Tumors Producing GHRH, GH, Ghrelin, PTH, or PTHrP 2015 , 125-139		1
55	GNAQ mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules. <i>Endocrine Pathology</i> , 2010 , 21, 250-2	4.2	1
54	Pharmacological approach to the treatment of acromegaly. <i>Neurosurgical Focus</i> , 2004 , 16, E3	4.2	1
53	The Classification of Pituitary Tumors: An Update. <i>Seminars in Neurosurgery</i> , 2001 , 12, 273-288		1
52	Physical performance in growth hormone- deficient adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 1839-40	5.6	1
51	Retraction. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2015 , 125, 3303	15.9	1

50	The Diagnosis of Neuroendocrine Neoplasms 2021 , 15-27		1
49	Chromatin remodeling: the interface between extrinsic cues and the genetic code?. <i>Clinical and Investigative Medicine</i> , 2008 , 31, E272-81	0.9	1
48	PANCREATIC INCIDENTALOMAS: IS IT NET OR NOT?. <i>Endocrine Practice</i> , 2016 , 22, 895-6	3.2	1
47	Prolactin, a potential biomarker for chronic GVHD activity. <i>European Journal of Haematology</i> , 2021 , 106, 158-164	3.8	1
46	Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer. <i>Oral Oncology</i> , 2021 , 121, 105477	4.4	1
45	Growth factors and their receptors in the genesis and treatment of thyroid cancer. <i>Cancer Treatment and Research</i> , 2004 , 122, 121-9	3.5	1
44	Re: Quality of life and symptom impact of thyroid cancer: A cross-sectional survey of Canadian patients. <i>Surgery</i> , 2019 , 166, 948-949	3.6	0
43	Ultrasound in active surveillance for low-risk papillary thyroid cancer: imaging considerations in case selection and disease surveillance. <i>Insights Into Imaging</i> , 2021 , 12, 130	5.6	0
42	Pharmacological options in the treatment of acromegaly. <i>Current Opinion in Investigational Drugs</i> , 2005 , 6, 1023-7		0
41	Molecular Pathogenesis of Pituitary Tumors 2017 , 165-175		
40	Molecular Predictors of Clinical Behavior in Pituitary Adenohypophysial Tumors. <i>Contemporary Endocrinology</i> , 2019 , 155-172	0.3	
39	Response to Miyauchi re: "A Prospective Mixed-Methods Study of Decision Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer". <i>Thyroid</i> , 2020 , 30, 1542-1543	6.2	
38	Mechanisms of pituitary tumorigenesis652-668		
37	Epigenetics of Pituitary Cell Growth and Survival 2014 , 101-110		
36	Signs and Symptoms of Pituitary Disease 2013 , 13-20		
35	Secondary Adrenal Insufficiency 2013 , 32-46		
34	Adult Growth Hormone Deficiency 2013 , 47-54		
33	Pituitary Carcinoma 2013 , 55-58		

- 32 Empty Sella Syndrome **2013**, 77-86
- 31 Familial Pituitary Adenomas **2013**, 87-110
- 30 Follicle Stimulating Hormone and Luteinizing Hormone Secreting Tumors **2013**, 111-119
- 29 Hypopituitarism **2013**, 120-129
- 28 Clinically Nonfunctioning Pituitary Adenomas **2013**, 130-137
- 27 Rathke's Cleft Cysts **2013**, 146-152
- 26 Thyroid Hormone Deficiency **2013**, 153-158
- 25 Thyroid Stimulating Hormone Secreting Tumor **2013**, 159-166
- 24 Pituitary Disorders Specific Issues for Women **2013**, 167-178
- 23 Hypogonadism and Male Sexual Function **2013**, 179-192
- 22 Pituitary Disorders Specific to Children **2013**, 193-203
- 21 Pituitary Endocrine Function Testing **2013**, 213-224
- 20 Surgical Management of Pituitary Disorders **2013**, 243-254
- 19 Medical Management of Pituitary Adenomas **2013**, 225-242
- 18 Stereotactic Radiosurgery for Pituitary Adenomas **2013**, 255-264
- 17 Hormone Replacement Therapy **2013**, 265-276
- 16 Complications of Pituitary Disease **2013**, 277-290
- 15 Living with Pituitary Disease **2013**, 301-310

14 Research and Clinical Trials **2013**, 311-322

13 Fundamentals of Pituitary Pathology **2013**, 323-332

12 Is autoimmune pituitary disease underdiagnosed?. *Nature Clinical Practice Endocrinology and Metabolism*, **2007**, 3, 678-9

11 Current views on pathogenesis of pituitary tumors. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2004**, 11, 281-286

10 The Pathophysiology of Pituitary Tumors. *Seminars in Neurosurgery*, **2001**, 12, 261-272

9 Pituitary Tumors, Molecular Pathogenesis **2004**, 681-686

8 Liver Transplantation in a Young Patient with Severe and Refractory Carcinoid Syndrome. *AACE Clinical Case Reports*, **2018**, 4, e289-e293 0.7

7 Is Hypothalamic Oxytocin Dispensable for Parturition?. *AACE Clinical Case Reports*, **2018**, 4, e437-e438 0.7

6 General Psychological and Psychosocial Effects of Pituitary Disorders 291-299

5 Prolactinoma 138-145

4 Thyroid Cancer Incidence and Endocrinologist Access: A Regional Data Analysis from Ontario, Canada. *Endocrine Practice*, **2016**, 22, 642-3 3.2

3 Epigenetics of Pituitary Cell Growth and Survival **2021**, 93-103

2 Pathology of pituitary growth hormone excess **2021**, 17-37

1 Pituitary Tumors; Diagnosis and Treatment **2018**, 257-257